Nail Involvement in Patients with Psoriatic Arthritis in Northern Iran
Table 1
Demographic and clinical characteristics of patients.
All patients (N= 197)
Patients without PsA (N=102)
Patients with PsA (N=95)
P Value
Age (Year, mean ±SD)
44.56 ± 14.73
44.93 ± 16.06
44.16 ± 13.24
0.71
Sex
Male
90 (45.7%)
51 (50%)
39 (41.1%)
0.21
Female
107 (54.3%)
51 (50%)
56 (58.9%)
Age at onset (Year, mean ±SD)
29.48 ± 17.00
31.87 ± 17.06
26.91 ± 16.65
0.04
Duration of psoriasis (Year, mean ±SD)
15.08 ± 10.78
13.06 ± 10.42
17.24 ± 10.79
0.006
Positive family history
82 (41.6%)
35 (34.3%)
47 (49.5%)
0.03
BMI, (kg/m2; mean ± SD)
28.97 ± 6.33
28.11± 6.05
29.95 ± 6.52
0.05
PASI
17.67 ± 10.53
15.37 ± 8.97
20.05 ± 11.54
0.01
Nail involvement
137 (69.5%)
59 (57.8%)
78 (82.1%)
0.001
Face involvement
127 (64.5%)
56 (54.9%)
71 (74.7%)
0.004
Genital involvement
126 (64%)
59 (57.8%)
67 (70.5%)
0.06
Smoking
32 (16.2%)
19 (18.6%)
13 (13.7%)
0.35
Alcohol
26 (13.2%)
14 (13.7%)
12 (12.6%)
0.82
Comorbidities
DM
36 (18.3%)
17 (16.7%)
19 (20%)
0.54
HTN
36 (18.3%)
17 (16.7%)
19 (20%)
0.54
CVD
11 (5.6%)
6 (5.9%)
5 (5.3%)
0.85
HLP
37 (18.8%)
20 (19.6%)
17 (17.9%)
0.76
Prior Treatments
Methotrexate
174 (88.3%)
85 (83.3%)
89 (93.7%)
0.024
Acitretin
122 (61.9%)
62 (60.8%)
60 (63.2%)
0.73
CyA
73 (37.1%)
27 (26.5%)
46 (48.4%)
0.001
Phototherapy
36 (18.3%)
13 (12.7%)
23 (24.2%)
0.04
Systemic steroids
21 (10.7%)
7 (6.9%)
14 (14.7%)
0.07
Biologics
64 (32.5%)
18 (17.6%)
46 (48.4%)
0.001
BMI: body mass index, PASI: psoriasis and area severity index, DM: diabetes mellitus, HTN: hypertension, CVD: cardio vascular disease, HLP: hyperlipidemia, and CyA: cyclosporine A.
